Popular Trials
Multi-kinase inhibitor
Elzovantinib for Solid Tumors
This trial is testing a new cancer drug to see if it is safe and effective. The study will first test increasing doses of the drug to see what the safe range is. Then, the study will expand to test the drug's effectiveness against different types of cancer.
Monoclonal Antibodies
Sacituzumab Govitecan + Capecitabine for Gastrointestinal Cancer
This trial is testing a new combination of drugs, sacituzumab govitecan and capecitabine, for patients with advanced gastrointestinal cancers that have not responded to standard treatments. Researchers
Checkpoint Inhibitor
Immunotherapy + Chemoradiation for Gastric Cancer
This trial is testing a combination of immunotherapy drugs, chemo, and radiation to treat gastric cancer. The hope is that the immunotherapy will help the body's immune system attack the cancer, and that the combination of treatments will be more effective than any one treatment alone.
Monoclonal Antibodies
Zolbetuximab Combination Therapy for Stomach Cancer
This trial is testing zolbetuximab, a medicine that helps the immune system attack stomach and gastroesophageal cancers with a specific protein. It targets patients whose tumors have the CLDN18.2 protein, aiming to improve their response to treatment.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for Gastric Adenocarcinoma Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
Zolbetuximab + Chemotherapy for Gastric or Gastroesophageal Junction Cancer
This trial will compare the effects of a new drug (zolbetuximab) on cancer progression, safety, and quality of life, compared to the standard treatment (placebo plus CAPOX).
Trials for Metastatic Patients
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for HER2 Positive Patients
Antibody-Drug Conjugate
T-DXd Combinations for Stomach Cancer
This trial is investigating the safety and preliminary effectiveness of a new cancer drug, trastuzumab deruxtecan (T-DXd), for treating HER2-positive gastric and esophageal cancers. The study will also look at whether T-DXd is more effective when given in combination with other cancer treatments.
Trials for PD-L1 Positive Patients
Checkpoint Inhibitor
Sonidegib + Pembrolizumab for Advanced Cancers
This trial tests the best dose of sonidegib combined with pembrolizumab for treating advanced solid tumors. Sonidegib blocks enzymes needed for tumor growth, while pembrolizumab helps the immune system attack cancer. The study focuses on patients with advanced cancers that have spread, aiming to find a more effective treatment than standard options.
Phase 3 Trials
Monoclonal Antibodies
Zolbetuximab + Chemotherapy for Gastric or Gastroesophageal Junction Cancer
This trial will compare the effects of a new drug (zolbetuximab) on cancer progression, safety, and quality of life, compared to the standard treatment (placebo plus CAPOX).
Alkylating agents
Chemotherapy + Radiotherapy for Esophageal and Gastric Cancer
This trial is studying how well adding radiotherapy to the usual chemotherapy treatment works compared to the usual treatment alone in treating patients with esophageal and gastric cancer.
Monoclonal Antibodies
Bemarituzumab + Chemotherapy for Stomach Cancer
This trial is testing whether adding bemarituzumab to standard chemotherapy helps patients live longer. It targets patients whose tumors have a specific marker (FGFR2b). The treatment works by blocking a protein that helps cancer cells grow.
Trials With No Placebo
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Monoclonal Antibodies
SGN-B6A for Cancer
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
View More Related Trials
Frequently Asked Questions
Introduction to gastric cancer
What are the top hospitals conducting gastric cancer research?
When it comes to cutting-edge clinical trials in the battle against gastric cancer, several top hospitals are leading the way. The M D Anderson Cancer Center in Houston has established itself as a frontrunner with four ongoing gastric cancer trials and an impressive track record of 18 completed studies since their inaugural trial in 2007. Meanwhile, at the Dana-Farber Cancer Institute in Boston, researchers are currently engaged in three active clinical trials for gastric cancer while having conducted a total of 19 previous studies since commencing research on this condition back in 2000.
It is worth noting that Memorial Sloan Kettering Cancer Center (All Protocol Activities) located in New york City demonstrates remarkable progress despite recording only one lifetime trial regarding gastric cancer; they have recently launched three active clinical investigations focusing on finding novel approaches towards combating this disease as early as last year -2020.The City of Hope Medical Center situated in Duarte also plays a significant role within this field, boasting three ongoing gastric cancer trials and contributing to elevating scientific understanding through participation among eleven previously held investigations originating from their initial experiment initiated around ten years ago-2011.Besides these accomplishments intersecting with Texas State,the University of Texas MD Anderson Cancer Center based out of Houston embarks upon similar initiatives showcasing revolutionary means regarding treating stomach cancers wherein they participate across series such as comprehensive groundbreaking research revolving around probing strategies for improvements by indulging into three contemporarily observed experiments pertaining specifically to Gastric Cancers along with expanding insights via seven preceding projects starting from their preliminary discovery about potential new paradigms nearly twelve years past till date.
These esteemed institutions not only offer hope but also provide platforms for innovation and collaboration. Every breakthrough made through these clinical trials brings us closer to improved treatment options and ultimately increases survival rates for individuals battling against gastric cancer globally
Which are the best cities for gastric cancer clinical trials?
When it comes to gastric cancer clinical trials, several cities emerge as leaders in research and development. Anchorage, Alaska boasts 18 active trials delving into treatments like Radiation Therapy and targeted therapies for specific mutations. Houston, Texas follows closely behind with 16 ongoing studies exploring innovative approaches such as Trastuzumab deruxtecan and combination therapies. Boston, Massachusetts also offers a robust landscape of 16 active trials investigating various treatment options. Los Angeles, California and New york, New York contribute significantly to gastric cancer research with their respective number of ongoing studies focused on different therapeutic interventions. These cities provide individuals battling gastric cancer access to cutting-edge clinical trials that hold promise for improving outcomes and advancing the field of care.
Which are the top treatments for gastric cancer being explored in clinical trials?
Exciting progress is being made in the field of gastric cancer treatment, with several cutting-edge therapies currently undergoing exploration in clinical trials. Notably, radiation therapy has emerged as a frontrunner, showing promise through three active trials and six all-time gastric cancer studies since 2016. Pembrolizumab follows closely behind with two ongoing trials and an impressive track record of 38 clinical trials dedicated to gastric cancer since its introduction in 2015. Equally noteworthy is trastuzumab deruxtecan, which entered the scene just last year but has already garnered attention for its involvement in two active and three all-time gastric cancer trials. Also making strides is nivolumab, engaged in two current investigations and having accumulated a respectable tally of 21 all-time clinical trials for gastric cancer since 2015. These advancements reflect the tireless efforts of researchers striving to improve outcomes for patients battling this challenging disease.
What are the most recent clinical trials for gastric cancer?
In the field of gastric cancer research, recent clinical trials offer promising advancements. One noteworthy trial is Arm B, which explores a combination of clinic-based and at-home treatments for gastric cancer patients. Additionally, Part B Expansion investigates new approaches to tackle this disease in its early stages. Another significant study focuses on the use of Olympus GIF 190 endoscope as a diagnostic tool in detecting gastric cancer. Furthermore, therapeutic options like gastrectomy with HIPEC have shown promise in Phase 2 trials. Finally, the investigation into Olaparib's effectiveness against gastric cancer marks another critical development. These ongoing trials hold great potential for improving outcomes and transforming the landscape of gastric cancer treatment moving forward.
What gastric cancer clinical trials were recently completed?
Several recent clinical trials have made significant contributions to the field of gastric cancer research. Noteworthy among them is a trial sponsored by OncXerna Therapeutics, Inc., which concluded in September 2019 and explored the potential benefits of Bavituximab. Additionally, City of Hope Medical Center's completed trial investigated Pembrolizumab in April 2019. Fate Therapeutics' FT500 study, completed in February 2019, also highlighted promising therapeutic avenues for this challenging disease. While these advances represent major strides forward, it is crucial to continue building upon their findings to further enhance treatment options for patients with gastric cancer.